|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Glucan-immunostimulant,adjuvant,potential drug显示文摘β-glucans belong to a group of biologically active natural compounds called biological response modifiers.These substances represent highly conserved structural components of cell walls in fungi,yeast,grain and seaweed.Despite almost 160 years of intensive research,the exact mechanisms of their action remain unsolved.The significant role of glucans in cancer treatment,infection immunity,stress reduction and restoration of damaged bone marrow has already been established.The present review focuses on the various less known but potentially significant roles glucans might play in medicine.In summary,glucan might represent the most important natural immunomodulator. | Vaclav Vetvicka | 2011 | World Journal of Clinical Oncology2011，2，2： | 8 |
| 2 | Endometriosis and ovarian cancer显示文摘Endometriosis is the leading cause of morbidity among premenopausal women and the complex pathogenesis of this disease remains controversial despite extensive research. This disease represents one of the most common gynecological problems. It is generally believed that this disease is due primarily to retrograde menstruation or transplantation of shed endometrium. Based on overwhelming data, ovarian endometrioma is considered a neoplastic process, since most endometriosis-associated ovarian carcinoma occur in the presence of atypical ovarian endometriosis. A study comparing patients with typical epithelial ovarian cancer with endometriosis-associated ovarian cancer demonstrated that the patients with the latter disease strongly differ in both biological and histological characteristics. The prevelance of this disease is not completely established, but approximately 15 percent of women suffer from this disease. In addition, we know about the possible links between endometriosis and cancer for almost 100 years. Despite clear evidence revealing that endometriosis increases ovariancancer risks, it is possible that it may not affect disease progression after the appearance of ovarian cancer. However, despite clear evidence revealing that endometriosis increases ovarian cancer risk, our knowledge of the risk factors is far from established. In our review, we focused on the most recent approaches including possible biomarkers and genetic approaches. | Milena Králí?ková Vaclav Vetvicka | 2014 | World Journal of Clinical Oncology2014，5，5： | 2 |
| 3 | Cathepsin D: Autoantibody profiling as a diagnostic marker for cancers显示文摘Current diagnostic assays for many cancers are antigen-based and rely on the detection of circulating proteins that are associated with a particular cancer.These assays depend on the expression,synthesis,and release of specific proteins by cells(e.g.,tumor cells)through either active secretion or shedding,or as a consequence of cell death(either necrosis or apoptosis).As such,these antigenic proteins must“escape”the primary site of disease,saturate the antigen-processing capacity of the individual’s immune components,gain access to the circulation,and reach a sufficient steady-state concentration to be detected by enzyme-or radiolabel-based immunoassays.These events usually occur after the initial establishment of disease.Thus,and despite the fact that certain specific antigenic epitopes exhibit common recognition among patients with the same tumor types,the use of these antigen-based cancer assays has not been widely accepted in clinical practice,and many individual countries differ in the use of these potential diagnostic factors.Lately,an increasing number of studies demonstrated that procathepsin D secreted from cancer cells,acts as a mitogen on cancer cells and stimulates their pro-invasive and pro-metastatic properties.In this report,we focused on the possibility to use antiprocathepsin D autoantibodies as a diagnostic and/or predictive marker for cancers. | Vaclav Vetvicka Martin Fusek | 2013 | World Journal of Clinical Oncology2013，4，1： | 2 |
| 4 | Soluble beta-glucan polysaccharide binding to the lectin site of neutrophil or natural killer cell complement receptor type 3 (CD11b/CD18) generates a primed state of the receptor capable of mediating cytotoxicity of iC3b-opsonized target cells显示文摘 | Vetvicka V Thornton BP Ross GD | 1996 | J Clin Invest1996，98，1： | 1 |
| 5 | Function of C3 in a humoral response:iC3b/C3dg bound to an immune complex generated with natural antibody and a primary antigen promotes antigen uptake and the expression of co-stimulatory molecules by all B cells,but only stimulates immunoglobulin synthesis by antigen-specific B cells显示文摘 | Thornton BP Vetvicka V Ross GD | 1996 | Clin Exp Immunol1996，104，3： | 1 |
| 6 | Beta-glucan,a specific biologic response modifier that uses antibodies to target tummors for cytotoxic recognition by leukocyte complement receptor type 3 (CD11b/CD18) 显示文摘 | Yan J VetvickA V Xia Y | 1999 | J Immunol1999，163，6： | 1 |
| 7 | Immuno- logical effects of yeast-and mushroom-derived beta-glucans 显示文摘 | Vetvicka V Vashishta A Saraswat-Ohri S | 2008 | J Med Food2008，11，4： | 1 |
| 8 | The beta-glucan-binding lectin site of mouse CR3(CD11b/CD18) and its function in generating a primed state of the receptor that mediates cytotoxic activation in response to iC3b-opo-nised target cells显示文摘 | Xia Y Vetvicka V Yah J | 1999 | J Immunol1999，162，4： | 1 |
| 9 | Reversal of perfluorooctanesulfonate-caused immunotoxicity by a glucan-resveratrol-vitamin C combination显示文摘 | Vetvicka V Vetvickova J | 2013 | Orient Pharm ExpMed2013，13，5： | 1 |
| 10 | β -Glucans, History, and the Present: Immunomodulatory Aspects and Mechanisms of Action显示文摘 | M. Novak V. Vetvicka | 2008 | Journal of Immunotoxicology2008，，1： | 1 |
| 11 | Cathepsin D many functions of one aspartic protease显示文摘 | Benes P Vetvicka V Fusek Met et aI | 2008 | Crit Rev Oncol Hematol2008，68，1： | 1 |
| 12 | Effects of marine beta-1, 3 glucan on immune reactions 显示文摘 | Vetvicka V Yvin JC | 2004 | lnt Immunopharmacol2004，4，6： | 1 |
| 13 | CR3 (CD11b, CD18): a phagocyte and NK cell membrane receptor with multiple ligand specificities and functions显示文摘 | Ross GD Vetvicka V | 1993 | Clin Exp Immunol1993，92，： | 1 |
| 14 | Biological prop- erties of (1-3)-D-glucan based synthetic oligosaccharides显示文摘 | Saraswat-Ohri S Vashishta A Vetvicka V | 2011 | J Med Food2011，14，4： | 1 |
| 15 | Pilot study : orally administered yeast β-gluean prophylactically protects against anthrax infection and cancer in mice 显示文摘 | VETVICKA V TERAYAMA K MANDEVILLE R | 2002 | J Am Nutracert Assoc2002，5，： | 1 |
| 16 | Beta-glucans, history, and the present: Immunomodulatory aspects and mechanisms of action 显示文摘 | Novak M Vetvicka V | 2008 | J Immunotoxicology2008，5，1： | 1 |
| 17 | Therapeutic intervention with complement and beta -glucan in cancer 显示文摘 | Ross G D Vetvicka V Yah J | 1999 | lmmunopharmacology1999，42，13： | 1 |
| 18 | Analysis of the sugar specificity and molecular location of the β-glucan-binding lectin site of complement receptor type 3 (CD11b/CD18)显示文摘 | THORTON B P VETVICKA V PITMAN M | 1996 | J Immunol1996，156，3： | 1 |
| 19 | Glucans as biological response modifiers显示文摘 | Novak M Vetvicka V | 2009 | Endocr Metab Immune Disord2009，9，1： | 1 |
| 20 | Immune enhancing effects of WB365,a novel combination of Ashwagandha (Withania somnifera) and Maitake (Grifola frondosa) extracts显示文摘 | Vetvicka V Vetvickova J | 2011 | N Am J Med Sci2011，3，7： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员